Chaoju Eye Care Holdings Limited disclosed on 29 September 2026 that its issued share capital remained unchanged at 701.46 million ordinary shares, with no treasury shares held. Key points from the filing:

1. Share Repurchase Activity • Between 31 August and 29 September 2026 the company bought back 2.87 million shares, equivalent to 0.41 % of the current issued share base. • The aggregate consideration for these repurchases was approximately HKD 7.03 million, implying a volume-weighted average purchase price of about HKD 2.45 per share. • The latest trade, executed on 29 September 2026, involved 70,000 shares repurchased on-market at prices between HKD 2.40 and HKD 2.45, costing HKD 0.17 million.

2. Status of Repurchased Shares • All 2.87 million shares bought since 31 August have been earmarked for cancellation but had not yet been cancelled as of the reporting date. • Once cancelled, the company’s issued share count would fall to roughly 698.59 million.

3. Repurchase Mandate Utilisation • The current general mandate, approved on 12 May 2026, authorises the repurchase of up to 70.52 million shares. • Cumulative repurchases under this mandate stand at 6.21 million shares, representing 0.88 % of the shares outstanding on the mandate date. • Approximately 64.31 million shares remain available for buyback under the existing authorisation.

4. Moratorium on New Issues • In line with Hong Kong Stock Exchange rules, the company is restricted from issuing new shares or transferring treasury shares until 29 October 2026, 30 days after the latest repurchase.

All repurchases were executed on the Hong Kong Stock Exchange and have been confirmed as compliant with the exchange’s Main Board Rules and other applicable regulations.